Our proprietary and advanced CAR-T and TCR-T immunotherapies to fulfill the unmet needs in cancer treatment
Biosyngen is developing first and best-in-class CAR-T and TCR-T cells targeting multiple solid tumors and lymphomas.
Our Pipeline
Biosyngen ongoing clinical trial against nasopharyngeal cancer, gastric cancer and lymphoma in multiple centers, filing Investigational New Drug application with CDE, FDA